Single-cycle neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: Final analysis of the RESET-C study. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results